HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone.

Abstract
Antagonists of growth hormone-releasing hormone (GHRH) were shown to inhibit the growth of various cancers. We investigated the antitumor activity and the mechanism of action of GHRH antagonists in human non-Hodgkin's lymphomas (NHL). Nude mice bearing xenografts of RL and HT human NHL were treated with GHRH antagonists MZ-5-156 and MZ-J-7-138 at a dose of 40 microg twice daily. The concentrations of serum IGF-1 and GHRH, bFGF, and VEGF in tumor tissue were measured by radioimmunoassays. Expression of GHRH and splice variant 1 of the GHRH receptor in both cell lines was examined by RT-PCR. The effects of MZ-5-156, MZ-J-7-138 and GHRH on cell proliferation were evaluated in vitro. Treatment with MZ-5-156 and MZ-J-7-138 significantly (P < 0.05) inhibited the growth of RL and HT tumors by 59.9-73.9%. High-affinity binding sites for GHRH and mRNA for GHRH and splice variant-1 of the GHRH receptors were found on RL and HT tumors. RL and HT cells contained GHRH peptide, and their growth in vitro was significantly inhibited by both antagonists. IGF-I levels in serum of mice were significantly decreased by antagonist MZ-5-156. Therapy with GHRH antagonists also significantly reduced tumoral bFGF, whereas VEGF levels were not suppressed. Our findings suggest that GHRH antagonists inhibit the growth of RL and HT lymphomas by direct effects mediated by tumoral receptors for GHRH. GHRH antagonists could offer a new therapeutic modality for the management of advanced NHL.
AuthorsGunhild Keller, Andrew V Schally, Kate Groot, Gabor L Toller, Alexandre Havt, Frank Köster, Patricia Armatis, Gabor Halmos, Marta Zarandi, Jozsef L Varga, Jörg B Engel
JournalProceedings of the National Academy of Sciences of the United States of America (Proc Natl Acad Sci U S A) Vol. 102 Issue 30 Pg. 10628-33 (Jul 26 2005) ISSN: 0027-8424 [Print] United States
PMID16027368 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • DNA Primers
  • MZ 5-156
  • Vascular Endothelial Growth Factor A
  • vascular endothelial growth factor A, mouse
  • Fibroblast Growth Factors
  • Insulin-Like Growth Factor I
  • Sermorelin
  • Growth Hormone-Releasing Hormone
Topics
  • Animals
  • Cell Line, Tumor
  • DNA Primers
  • Dose-Response Relationship, Drug
  • Female
  • Fibroblast Growth Factors (metabolism)
  • Growth Hormone-Releasing Hormone (antagonists & inhibitors, blood)
  • Humans
  • Insulin-Like Growth Factor I (metabolism)
  • Lymphoma, Non-Hodgkin (drug therapy)
  • Mice
  • Mice, Nude
  • Radioimmunoassay
  • Reverse Transcriptase Polymerase Chain Reaction
  • Sermorelin (analogs & derivatives, pharmacology, therapeutic use)
  • Vascular Endothelial Growth Factor A (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: